Clostridioides difficile (C. difficile) is the major cause of nosocomial antibiotic-associated diarrhea. Clostridium butyricum, one of the most common used probiotics had been proven effective in many kinds of gastrointestinal disease. Supernatants of C. butyricum MIYAIRI 588 strain (CBM588) was shown to exhibit potent inhibitory effect on C. difficile. Heat-labile and pH-labile characteristics of the supernatant from CBM 588 suggested that a proteinaceous substance is involved in inhibiting C. difficile growth in vitro. Recombinant CBM 588 bacteriocin (CBM-B) was constructed and demonstrated to have inhibitory effect against C. difficile. CBM-B was unable to alter spore germination efficiency and outgrowth. When applied at sub-lethal concentration, CBM-B could suppress tcdA and tcdB expression in part by decreasing the expression of a toxin regulator. Intra-rectal administration of CBM-B, combined with vancomycin revealed less body weight reduction and less C. difficile bacterial load in feces in mice model with CDI compared to CBM-B or vancomycin single use. In conclusion CBM-B from CBM 588 is a potential inhibitor against C. difficile which could be used as therapeutic treatment for CDI.
|Original language||American English|
|State||Published - 12 Jun 2022|
|Event||American Society for Microbiology General Meeting: ASM Microbe 2022 - Walter E. Washington Convention Center, Washington, United States|
Duration: 9 Jun 2022 → 13 Jun 2022
|Conference||American Society for Microbiology General Meeting|
|Period||9/06/22 → 13/06/22|